The Omicron variant of the coronavirus is causing a dramatic rise in cases of croup, a dangerous respiratory condition usually seen in babies and toddlers, new data suggest. Additionally, new research sheds light on how a tuberculosis vaccine might help protect against COVID-19.

GSK

Britain’s GSK halted enrollment and vaccination in three trials of the company’s experimental vaccine against the respiratory syncytial virus (RSV) in pregnant women, the latest setback in developing a vaccine for the microbe.

The CEO of Maryland-based Novavax believes U.S. Emergency Use Authorization (EUA) for the company’s protein-based COVID-19 vaccine could happen “within weeks.”

GlaxoSmithKline will move the company’s experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing after experiencing encouraging mid-stage trial results.